Centrinone Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

633.65

DMSO: 31mg/mL (48.92mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

C26H25F2N7O6S2

FC(C([N+]([O-])=O)=CC=C1)=C1CS(C2=CC(F)=C(SC3=NC(NC4=NNC(C)=C4)=C(OC)C(N5CCOCC5)=N3)C=C2)(=O)=O

1798871-30-3

PLK4: ic50 0.16nM (ki)
PLK4 G95L: ic50 68.57nM (ki)
Aurora A: ic50 171nM (ki)
Aurora B: ic50 436.76nM (ki)

Centrinone treatment, causes centrosome depletion in human and other vertebrate cells and reduces centriole number in multiciliated Xenopus epithelial cells. Centrinone treatment of HeLa human cervical carcinoma cells leads to a progressive reduction in foci containing centriolar and pericentriolar material markers at each round of cell division until most cells lack centrioles and centrosomes. Centrosome loss irreversibly arrests normal cells in a senescence-like G1 state by a p53-dependent mechanism that is independent of DNA damage, stress, Hippo signaling, extends mitotic duration, or segregation errors.

Cell Cycle/Checkpoint; Aurora Kinase; Chromatin/Epigenetic